Novel combinations targeting other immune checkpoints, such as anti-LAG-3 or anti-TIM-3 antibodies, are under exploration in phase II studies, particularly for NETs with higher proliferative indices, such as pulmonary atypical carcinoids with high tumor-infiltrating lymphocytes or MMR-deficient NETs, that might benefit from immunotherapy [125,126]. Here, MRC1 is linked to neoplasm.